Effects of Allopurinol on the Progression of Chronic Kidney Disease
Sunil V Badve, Elaine M Pascoe, M Biostat, Anushree Tiku, Neil Boudville, Fiona G Brown, Alan Cass, Philip Clarke, Nicola Dalbeth, Richard O Day, Janak R de Zoysa, Bettina Douglas, Randall Faull, David C Harris, Carmel M Hawley, Graham RD Jones, John Kanellis, Suetonia C Palmer, Vlado Perkovic, Gopala K Rangan Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2020
BACKGROUND: Elevated serum urate levels are associated with progression of chronic kidney disease. Whether urate-lowering treatment with allopurinol can attenuate the decline of the estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease who are at risk for progression is not known. METHODS: In this randomized, controlled trial, we randomly assigned adults with stage 3 or 4 chronic kidney disease and no history of gout who had a urinary albumin:creatinine ratio of 265 or higher (with albumin measured in milligrams and creatinine in grams) or an eGFR decrease of at least 3.0 ml per minute per 1.73 m2 of body-surface area in the preceding year to receive allopurinol..View full abstract
Awarded by National Health and Medical Research Council of Australia
Awarded by Health Research Council of New Zealand
Supported by grants from the National Health and Medical Research Council of Australia (APP1043203) and the Health Research Council of New Zealand (14/117).